whether angiotensin receptor blockers increase cancer or cardiovascular risk
August 2010
See updated FDA information regarding ARBs/cancer and Olmesartan/CV risks
ARBs and cancer. A recent meta-analysis started a buzz that ARBs might lead to a small increased cancer risk...about 1 more case for every 143 patients using an ARB instead of placebo for 4 years.
One theory is that angiotensin might be involved in cell growth. ARBs increase free angiotensin by blocking its receptors.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote